Author

Delgado Francisco R

Hospital Universitario Central de Asturias - Cited by 1,308 - Gastroenterolog

Biography

Delgado Francisco R  is a versatile author in the field of chemical sciences and pharmacological studies on natural products. And has dedicated their major research contributions in the field of natural medicine, phytomedicine, bioactive compounds, herbal drugs, phytochemistry, etc.
Title
Cited by
Year
Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry
M Iborra, B Beltrán, A Fernández‐Clotet, A Gutiérrez, B Antolín, ...Alimentary pharmacology & therapeutics 50 (3), 278-288, 2019201
59
2019
Increased risk of thiopurine‐related adverse events in elderly patients with IBD
M Calafat, M Mañosa, F Cañete, E Ricart, E Iglesias, M Calvo, ...Alimentary pharmacology & therapeutics 50 (7), 780-788, 2019201
38
2019
Adalimumab or infliximab for the prevention of early postoperative recurrence of Crohn disease: results from the ENEIDA Registry
F Cañete, M Mañosa, MJ Casanova, RC González-Sueyro, J Barrio, ...Inflammatory bowel diseases 25 (11), 1862-1870, 2019201
29
2019
Extraintestinal manifestations in patients with inflammatory bowel disease: study based on the ENEIDA Registry
A Algaba, I Guerra, E Ricart, E Iglesias, M Mañosa, JP Gisbert, ...Digestive Diseases and Sciences 66, 2014-2023, 2021202
26
2021
Long-term real-world effectiveness and safety of ustekinumab in Crohn’s disease patients: the SUSTAIN study
M Chaparro, I Baston-Rey, E Fernández-Salgado, J González García, ...Inflammatory Bowel Diseases 28 (11), 17-1736, 2022202
25
2022
Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn’s disease: analysis from the PRACTICROHN study
A Gutiérrez, M Rivero, MD Martín-Arranz, V García Sánchez, M Castro, ...Gastroenterology Report 7 (3), 168-175, 2019201
21
2019
12
2021
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents
M Guasch, F Cañete, I Ordás, E Iglesias‐Flores, A Clos, JP Gisbert, ...Journal of Gastroenterology and Hepatology 35 (12), 2080-2087, 2020202
11
2020
I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease
L Peyrin-Biroulet, JF Rahier, J Kirchgesner, V Abitbol, S Shaji, A Armuzzi, ...Clinical Gastroenterology and Hepatology 21 (3), 771-7. e10, 2023202
8
2023
Immigrant IBD patients in Spain are younger, have more extraintestinal manifestations and use more biologics than native patients
A Gutiérrez, P Zapater, E Ricart, M González-Vivó, J Gordillo, D Olivares, ...Frontiers in Medicine 9, 83900, 0
2
2022
Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study
MJ Casanova, Ó Nantes, P Varela, M Vela‐González, M Rivero, ...Alimentary Pharmacology & Therapeutics, 2023202
1
2023
Clinical presentation, management, and evolution of lymphomas in patients with inflammatory bowel disease: an ENEIDA registry study
I Guerra, L Bujanda, M Mañosa, I Pérez-Martínez, MJ Casanova, ...Cancers 5 (3), 750, 2023202
1
2023
Using interpretable machine learning to identify baseline predictive factors of remission and drug durability in Crohn’s disease patients on ustekinumab
M Chaparro, I Baston-Rey, E Fernández Salgado, J González García, ...Journal of clinical medicine (5), 458, 2022202
1
2022
Eficacia y seguridad de la pinza disectora SB Knife™ Jr. en el tratamiento del divertículo de Zenker: Serie de casos
AG Outomuro, ÓG Bernardo, IP Martínez, AC García, CR Escaja, ...Revista Española de Enfermedades Digestivas 2 (3), 26-28, 2020202
1
2020